AQR Capital Management Expands Chemed Corp (CHE) Stake -- Shares Look 22% Undervalued on GF Value
AQR Capital Management significantly increased its stake in Chemed Corp (CHE), purchasing 556,862 shares. The stock has appreciated since the acquisition and is considered 22% undervalued based on GuruFocus's GF Value, suggesting confidence in its long-term prospects. Chemed Corp, operating in hospice care (VITAS) and plumbing services (Roto-Rooter), exhibits robust financial health and strong operational efficiency, making it an appealing consideration for long-term investors.
Chemed Corp (CHE) Investor Outlook: Exploring Growth Potential With A 3.59% Upside
Chemed Corp (NYSE: CHE), a diversified healthcare company operating through its VITAS hospice and Roto-Rooter plumbing segments, is currently trading at $532.88 with a potential upside of 3.59% based on analyst target prices. The company demonstrates strong financial health with 8.80% revenue growth, a 27.11% return on equity, and a solid free cash flow of $307.86 million. While technical indicators suggest the stock is nearing overbought territory, analyst ratings lean cautiously optimistic, highlighting Chemed's unique position in essential services and healthcare.
Focus Partners Advisor Solutions LLC Makes New $998,000 Investment in Chemed Corporation $CHE
Focus Partners Advisor Solutions LLC invested $998,000 in Chemed Corporation by purchasing 2,142 shares during the second quarter. Chemed reported strong quarterly results, exceeding earnings expectations and showing an 8.8% year-over-year revenue increase, leading the company to raise its quarterly dividend. Analysts generally hold a "Hold" rating for Chemed, with an average price target of $530.75.
Chemed Corp (CHE) Stock Forecasts
Argus has lowered its target price for Chemed Corp (CHE) to $564.00, citing the company's business activities of purchasing, operating, and divesting subsidiaries to maximize shareholder value. As of the report date, Chemed Corp's current price is $540.25. The report suggests upgrading to premium research for more detailed insights.
Chemed Corp VP Brian C. Judkins Executes Stock Option Exercise and Sells Shares on August 10, 2026
Brian C. Judkins, VP and Chief Legal Officer of Chemed Corp (NYSE: CHE), filed a Form 4 on August 10, 2026. The filing discloses that Judkins exercised stock options and subsequently disposed of shares on the same date.
Chemed Corp (CHE) legal chief exercises 6,786 options, withholds 5,878 shares
Brian C. Judkins, VP and Chief Legal Officer of Chemed Corp (CHE), exercised stock options for 6,786 shares at an exercise price of $445.35 per share. To cover the purchase and tax obligations, 5,878 shares were withheld at $548.96 per share. Following this transaction, Judkins retains 31,281 option-based shares and 3,344 shares of capital stock.
Chemed Corporation $CHE Shares Sold by Quantinno Capital Management LP
Quantinno Capital Management LP significantly reduced its stake in Chemed Corporation (NYSE:CHE) by 55.5% in the first quarter, selling 8,251 shares but still retaining 6,603 shares valued at approximately $2.49 million. This comes as Chemed reported strong quarterly earnings, beating estimates with EPS of $6.06 and an 8.8% revenue increase, along with a dividend hike to $0.70 per share. Despite institutional ownership of 95.85% and some analyst upgrades, the stock maintains a consensus "Hold" rating.
Chemed Corp stock hits 52-week high at 552.05 USD By Investing.com
Chemed Corp's stock has reached a new 52-week high of $552.05, demonstrating strong performance with a 28.75% year-to-date return and a 25.86% increase over the past year. This milestone follows the company's strong second-quarter earnings, which surpassed Wall Street expectations due to growth in its VITAS hospice unit and Roto-Rooter. InvestingPro analysis suggests the stock is undervalued, noting its 17-year streak of dividend increases.
Chemed Corporation (NYSE:CHE) to Issue Dividend Increase - $0.70 Per Share
Chemed Corporation (NYSE:CHE) announced a 16.7% increase in its quarterly dividend to $0.70 per share, payable on September 3rd to shareholders of record on August 17th. This marks the 16th consecutive year the company has raised its dividend, demonstrating strong earnings coverage with a current payout ratio of 8.7%. Chemed also surpassed Q2 earnings expectations, reporting $6.06 adjusted EPS on revenues of $673.25 million.
Chemed Corp (CHE) Stock News Today
This page provides current stock news, earnings, analyst ratings, and key developments for Chemed Corp (CHE). The article states that more news will be available soon. It also includes basic financial data such as the stock price, market cap, and P/E ratio.
Chemed Corp stock hits 52-week high at 552.05 USD
Chemed Corp's stock reached a new 52-week high, closing at 552.05 USD, reflecting strong performance and investor confidence. The company's market capitalization is 7.15 billion USD, with impressive year-to-date returns of 28.75% and a 1-year increase of 25.86%. InvestingPro analysis suggests the stock is undervalued and highlights its 17-year streak of consecutive dividend increases.
Understanding Momentum Shifts in (CHE)
This article analyzes Chemed Corp (NYSE: CHE) using AI models to identify potential momentum shifts. Key findings suggest that strong near and mid-term sentiment could extend to the long term, with no resistance levels above the current price, indicating upside potential. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for CHE.
Chemed Corp stock hits 52-week high at 552.05 USD By Investing.com
Chemed Corp's stock has reached a new 52-week high of $552.05, demonstrating strong performance with a 28.75% year-to-date return and a 25.86% increase over the past year. This achievement follows robust second-quarter earnings, where the company surpassed Wall Street expectations with adjusted earnings of $6.06 per share and revenue of $673.25 million, driven by its VITAS hospice unit and Roto-Rooter. The company has also maintained a 17-year streak of dividend increases and has uplifted its outlook for the remainder of the year.
Chemed Corp (CHE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Chemed Corp (CHE), highlighting its current price momentum score of 3.68 and its position within the Healthcare Providers & Services industry. It details the stock's support and resistance levels, and analyzes various technical indicators and moving averages, concluding with a neutral signal based on these factors.
Chemed Corporation (CHE) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Chemed Corporation (CHE) stock, including its current price, performance metrics, key financial data, and analyst insights. It details the company's operations in hospice care through VITAS and plumbing services via Roto-Rooter, along with its historical performance against the S&P 500. The page also offers valuation measures, profitability highlights, and comparisons with similar companies in the medical care facilities industry.
Chemed Corp (NYSE: CHE) executive exercises 2,599 options, 2,270 shares withheld
Chemed Corp executive Joel L. Wherley, CEO of Vitas Healthcare, exercised 2,599 stock options at $445.35 per share on August 5, 2026. Simultaneously, 2,270 shares were withheld at $542.62 per share to cover the purchase price and tax obligations. Following this transaction, Wherley directly holds 30,220 shares of Chemed Corp capital stock.
Segall Bryant & Hamill LLC Invests $2.29 Million in Chemed Corporation $CHE
Segall Bryant & Hamill LLC has initiated a new position in Chemed Corporation (NYSE:CHE) by purchasing 5,695 shares valued at $2.29 million. Chemed exceeded its recent quarterly earnings expectations, reporting $6.06 EPS against an estimate of $5.60 and revenue of $673.25 million, an 8.8% year-over-year increase. Despite analyst "Hold" ratings and significant insider selling, the company issued strong full-year 2026 EPS guidance and pays a quarterly dividend.
Insider Selling: Chemed (NYSE:CHE) CEO Sells $1,079,020.00 in Stock
Chemed CEO Kevin McNamara sold 2,000 shares of the company's stock for $1,079,020.00, reducing his direct ownership by 2.76%. Despite the insider selling and a slight dip in stock price, Chemed reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend. Analysts generally maintain a "Hold" rating for the stock, with institutional investors holding a significant portion of shares.
Chemed (NYSE: CHE) CEO sells 2,000 shares after exercising stock options
Chemed Corp President and CEO Kevin J. McNamara exercised stock options for 2,001 shares at $445.35 and subsequently sold 2,000 shares of capital stock at a weighted average price of $539.51. An additional 19,802 shares were withheld to cover the option purchase price and related tax obligations. Following these transactions, McNamara directly holds 264,158 stock options.
Chemed director Patrick Grace sells $101,080 in company stock
Patrick P. Grace, a director at CHEMED CORP (NYSE:CHE), recently sold 190 shares of company stock for a total of $101,080 at $532.0 per share. This transaction occurred on July 31, 2026, with the stock trading near its 52-week high and up 25% year-to-date. The sale follows a strong second-quarter earnings report where Chemed surpassed Wall Street expectations, driven by growth in its hospice unit and consistent results from Roto-Rooter.
Chemed (NYSE:CHE) Director Sells 190 Shares
Chemed (NYSE:CHE) Director Patrick Grace sold 190 shares of the company's stock for $101,080, reducing his direct ownership by 5.1%. This sale occurred on July 31st when shares traded at an average price of $532.00. Following the sale, Chemed shares rose 1.7% to $541.38, nearing their 12-month high, after the company reported strong quarterly earnings and revenue growth.
Chemed director Patrick Grace sells $101,080 in company stock By Investing.com
Chemed director Patrick P. Grace sold 190 shares of the company's capital stock for $101,080 on July 31, 2026. This transaction occurred while CHEMED stock is trading near its 52-week high, with shares up 25% year-to-date. The company recently surpassed Wall Street expectations with strong Q2 2026 earnings, driven by growth in its hospice unit, VITAS, and consistent performance from Roto-Rooter.
Chemed director Patrick Grace sells $101,080 in company stock
Chemed director Patrick Grace sold 190 shares of the company's capital stock for $101,080 on July 31, 2026. This transaction occurred as CHEMED stock traded near its 52-week high, with shares up 25% year-to-date. The company recently surpassed Wall Street expectations for its second-quarter earnings, driven by strong growth in its VITAS hospice unit and consistent results from Roto-Rooter.
Chemed (NYSE: CHE) director sells 190 shares at $532 in open trade
Chemed director Patrick P. Grace sold 190 shares of Capital Stock on July 31, 2026, at a price of $532.00 per share. This transaction was an open market sale and was not made under a Rule 10b5-1 trading plan. Following the sale, Grace directly owns 3,533 shares of Chemed stock.
Chemed (NYSE:CHE) Raised to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Chemed (NYSE:CHE) from "hold" to "strong-buy," despite the broader analyst consensus remaining "Hold" with an average price target of $530.75. This upgrade follows Chemed's strong quarterly performance, where earnings per share and revenue exceeded expectations. The company's stock opened near its 52-week high, with institutional investors holding a significant stake, although an insider recently reduced their holdings.
CHE Maintained by Oppenheimer -- Price Target Raised to $590
Oppenheimer has maintained an "Outperform" rating for Chemed Corp (CHE), raising its price target to $590 from $500, an 18% increase. Despite insider selling, the company is considered 21.1% undervalued according to GuruFocus's GF Value™ and holds a strong GF Score™ of 88/100, indicating robust financial health and profitability. This suggests a potential buying opportunity for investors, driven by the company's strong business model in healthcare and plumbing services.
CHEMED CORP Q2 2026: Revenue $673.3M, EPS $5.13— 10-Q Summary
CHEMED CORP reported strong second-quarter 2026 results, with revenue reaching $673.3 million and diluted EPS at $5.13. This growth was primarily driven by the performance of VITAS hospice services and improved pricing and mix at Roto-Rooter, leading to a significant increase in net income.
CHE Q2 Deep Dive: VITAS Growth and Roto-Rooter Marketing Pressures Shape Outlook
Chemed Corporation reported better-than-expected Q2 CY2026 results, driven by strong patient volume growth and improved admission trends at VITAS. While VITAS growth and disciplined cost management are positives, Roto-Rooter faces challenges with increased marketing spend due to a higher reliance on paid leads. The company's full-year outlook is optimistic, supported by continued VITAS expansion and strategic acquisitions, but Roto-Rooter's marketing efficiency remains a key focus.
Chemed Corporation (NYSE:CHE) Given Consensus Rating of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Chemed Corporation (NYSE:CHE), with an average 12-month price target of $480.25. The company recently surpassed second-quarter earnings and revenue expectations, reporting adjusted EPS of $6.06 and revenue of $673.3 million. Following strong performance, particularly from its VITAS segment, Chemed raised its full-year 2026 adjusted EPS guidance to $25.00–$25.75.
Chemed Corporation Q2 2026 Earnings Call Summary
Chemed Corporation's Q2 2026 earnings call highlighted strong performance from both VITAS and Roto-Rooter divisions. VITAS exceeded expectations due to increased admissions and efficient cost management, leading to raised full-year guidance. Roto-Rooter adapted to declining free internet leads by shifting to paid leads and focusing on high-margin ancillary services, while also strategically repurchasing franchises.
Chemed Corp (CHE) Institutional Confidence
Chemed Corp (CHE) has an institutional shareholding score of 10.00, placing it at the top of its industry. The institutional shareholding proportion is 105.26%, with a slight quarter-over-quarter decrease. ETHSX is the largest institutional shareholder, significantly increasing its holdings in the company.
Chemed Corp (CHE) Q2 2026 Earnings Call Highlights: Strong Vitas Performance and Strategic ...
Chemed Corporation (CHE) reported strong performance in Q2 2026, driven by Vitas Healthcare's accelerated admissions and controlled labor costs, leading to higher revenue and EBITDA margins. Roto Rooter also saw increased commercial sales, but faced challenges with lead generation costs and declines in water restoration revenue and independent contractor business. Executives addressed concerns regarding lead acquisition, Vitas's long-term growth, and Roto Rooter's expansion strategies during the Q&A session.
Chemed Q2 Results: EPS rises 43.7%, VITAS drives growth
Chemed Corporation has raised its full-year 2026 adjusted diluted EPS guidance to $25.00-$25.75, exceeding analyst estimates, following strong Q2 results. This upward revision is primarily driven by the robust performance of its VITAS Healthcare segment, which saw a significant increase in net patient revenue and a dramatic reduction in Medicare Cap billing limitations. In contrast, the Roto-Rooter segment showed muted profitability due to rising SG&A expenses, highlighting shifting operational dynamics within the company.
Chemed Reports Second-Quarter 2026 Results
Chemed Corporation reported strong second-quarter 2026 results, with consolidated revenue increasing by 8.8% to $673.3 million and adjusted diluted EPS up 41.9% to $6.06. The company raised its full-year guidance, primarily due to VITAS Healthcare's outperformance, while Roto-Rooter's performance met expectations. VITAS saw an 11.9% increase in net patient revenue and a significant reduction in Medicare Cap billing limitation compared to the prior year.
Chemed Reports Second-Quarter 2026 Results
Chemed Corporation announced its second-quarter 2026 financial results, with significant outperformance primarily driven by its VITAS Healthcare segment. Revenue increased by 8.8% to $673.3 million, and adjusted diluted EPS rose by 41.9% to $6.06. The company has also raised its full-year 2026 guidance, expecting diluted EPS between $25.00 and $25.75, an increase largely credited to VITAS's strong performance and share repurchases.
Chemed earnings up next: Can VITAS momentum sustain premium?
Chemed Corp is scheduled to report its second-quarter earnings today, with analysts expecting $5.60 per share on $665.04 million in revenue. Investors will focus on the performance of its VITAS Healthcare hospice division and the growth strategy for its Roto-Rooter plumbing services unit. The market is keenly watching whether the company can justify its premium valuation and sustain its recent momentum amid its near 52-week high stock price.
Chemed Corporation $CHE Stock Position Cut by NewEdge Wealth LLC
NewEdge Wealth LLC significantly reduced its stake in Chemed Corporation (NYSE:CHE) by 50.8% in the first quarter, selling 2,143 shares and retaining 2,078 shares valued at approximately $785,000. Despite this reduction, institutional investors collectively own 95.85% of Chemed's stock, with several firms substantially increasing their positions. Analysts maintain a "Hold" rating on Chemed, with a consensus target price of $480.25, while the company pays a quarterly dividend of $0.60 per share.
Chemed Corp (CHE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical timeline of dividend payouts for Chemed Corp (CHE), detailing interim and final cash dividends with their respective record dates, payment dates, and ex-dividend dates. It shows that Chemed Corp has distributed a total of $94.63 million in dividends over the past five years. The stock's current market cap is $6.73 billion with a P/E TTM of 27.71.
Avoiding Lag: Real-Time Signals in (CHE) Movement
This article provides an AI-generated analysis of Chemed Corp (NYSE: CHE) focusing on real-time signals, sentiment, and trading strategies. Key findings indicate a neutral near-term outlook with potentially stalling mid-term strong sentiment. The analysis includes specific long, breakout, and short trading strategies with entry points, targets, and stop losses.
Chemed Corp (CHE) Cash Flow
This article provides a detailed historical cash flow statement for Chemed Corp (CHE), including operating, investing, and financing cash flows, presented quarterly and annually. It offers insights into the company's financial soundness and stability, with key financial metrics like market cap and P/E ratio. The article also includes FAQs defining different types of cash flow and their significance for investors.
Chemed Corp (CHE) Income Statement - Tradingkey.com
This article provides a detailed quarterly income statement for Chemed Corp (CHE), including revenue, expenses, operating profit, and net income, spanning several fiscal years. It also includes key financial metrics like EPS and dividend per share. The piece offers FAQs to help users interpret the income statement and understand various financial terms.
California Public Employees Retirement System Decreases Stock Holdings in Chemed Corporation $CHE
The California Public Employees Retirement System significantly cut its holdings in Chemed Corporation (NYSE:CHE) by 17.0% in the first quarter, selling 6,438 shares and retaining 31,520 shares valued at approximately $11.9 million. Despite this, Chemed reported strong quarterly earnings per share of $5.65, surpassing analyst estimates, and declared a $0.60 per share quarterly dividend. Institutional investors collectively own 95.85% of Chemed's stock, highlighting significant institutional interest despite some recent sales.
Epoch Investment Partners Inc. Sells 72,285 Shares of Chemed Corporation $CHE
Epoch Investment Partners Inc. significantly reduced its stake in Chemed Corporation (CHE) by 22.4% in the first quarter, selling 72,285 shares. Other institutional investors showed mixed activity, while Chemed's CEO and a director also sold shares. The company has a consensus "Hold" rating from analysts, despite beating recent EPS expectations.
CHE|Chemed Corp|Price:511.130|Chg%:+8.307
Chemed Corp's fundamentals are healthy, and its growth potential is high, with the stock considered fairly valued within the Healthcare Providers & Services industry. Institutional ownership is significant, and analysts generally rate it as a "Buy," with expectations for a medium-term upward trend in stock price. However, despite strong fundamentals, technical analysis suggests the stock is currently trading sideways between support and resistance levels.
Chemed Corp (CHE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Chemed Corp (CHE), highlighting its current valuation score of 8.02 and its ranking within the Healthcare Providers & Services industry. It notes the company's current P/E ratio relative to its recent high and low, but states that P/B, P/S, and P/CF data are not yet disclosed. The content emphasizes that TradingKey offers general investment information and not financial advice.
Chemed Corp (CHE) Stock forecasts
Argus has raised its target price for Chemed Corp (CHE) to $529.00, citing the company's strategy of acquiring, operating, and divesting subsidiaries to enhance shareholder value. The healthcare sector company is currently trading at $511.13. Investors can access a full report for more detailed analysis.
Chemed Corp Revenue Breakdown – NYSE:CHE
Chemed Corp (NYSE:CHE) generated $2.53 billion USD in revenue last year. The majority of this revenue, $1.63 billion USD, came from its top-performing VITAS segment, an increase from $1.53 billion USD the previous year. The United States was the primary contributor to the company's revenue, accounting for $2.53 billion USD.
3 Reasons to Sell CHE and 1 Stock to Buy Instead
This article recommends selling shares of Chemed (CHE) due to disappointing long-term revenue growth, barely growing earnings per share, and declining return on invested capital. While acknowledging Chemed is not a terrible business, the analysis suggests better investment opportunities exist elsewhere. The article also promotes a separate service for identifying alternative stock picks.
Barington Capital pushes Chemed for strategic review
Activist investor Barington Capital Group is pressuring Chemed Corp. to undertake a strategic review and refresh its board of directors. Barington believes Chemed's two businesses, hospice provider Vitas Healthcare and Roto-Rooter, are undervalued, arguing the company has underperformed its peers. The investor is also advocating for cost reductions, a revised executive compensation program, and new board representation.
Chemed (CHE) Expected to Release Quarterly Earnings on Tuesday
Chemed (CHE) is anticipated to release its Q2 2026 earnings after the market closes on Tuesday, July 28th, with analysts forecasting earnings per share of $5.55 and revenue of $665.0 million. The company's earnings call is set for Wednesday, July 29th at 10:00 AM ET. Chemed previously reported stronger-than-expected profits in Q1, and analysts currently maintain a "Hold" consensus rating for the stock, with an average price target of $480.25.
